Mylan Jumps After Settling With DOJ for $465 Million
EpiPen maker Mylan jumped more than 9% Monday morning following its announcement that it reached a $465 million settlement with the U.S. Department of Justice.
Embattled EpiPen maker Mylan jumped more than 9% Monday morning following its announcement that it reached a $465 million settlement with the U.S. Department of Justice over how the company charged Medicaid for its EpiPen allergy shot. There had been concerns that the penalty for the company could have been more than double that amount. As part of the settlement, Mylan admitted no wrongdoing while the agreement resolves "all potential rebate liability claims by federal and state governments."
